Radioactive therapy shows promise in Late-Stage gut cancer trial
NCT ID NCT05884255
First seen May 10, 2026 · Last updated May 14, 2026 · Updated 1 time
Summary
This phase 3 trial tests a radioactive drug (lutetium-177) combined with standard-dose octreotide against high-dose octreotide alone in 220 adults with advanced gastrointestinal or pancreatic neuroendocrine tumors that cannot be removed by surgery. The goal is to see if the combination slows tumor growth better than the standard high-dose therapy. Participants must have low- or medium-grade tumors and be in good overall health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact
Conditions
Explore the condition pages connected to this study.